AB-Biotics to collaborate with Cilag GmbH to develop probiotic to fight gingivitis
<p>The subsidiary of Johnson&Johnson will have the option to license the probiotic exclusively around the world</p>
Catalan biotechnology firm AB-Biotics has signed an agreement with a subsidiary of Johnson&Johnson, Cilag GmbH International, to collaborate on developing AB-Gingilac, a probiotic to prevent and treat gingivitis. The agreement offers the Johnson&Johnson subsidiary the option to exclusive global licensing and exploitation rights to the probiotic.
In the first phase, Cilag GmbH will invest in a clinical study on the product, which will be developed by AB-Biotics in Spain and coordinated by professor Mariano Sanz, professor of Periodontics at the Complutense University of Madrid.
AB-Gingilac is part of a line of probiotics for oral health being developed by AB-Biotics and features a probiotic formula made up of various strains of bacteria that aims to fight gingivitis, one of the most common chronic inflammatory diseases.